Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series
Authors
- Kazumoto Shibuya (ORCID: https://orcid.org/0000-0003-4061-0412)
- Satoshi Kuwabara (ORCID: https://orcid.org/0000-0002-4716-8578)
- Emiko Sakaida (ORCID: https://orcid.org/0000-0002-7254-1928)
- Shokichi Tsukamoto (ORCID: https://orcid.org/0000-0003-4314-893X)
- Naoya Mimura (ORCID: https://orcid.org/0000-0002-1717-9428)
- Sonoko Misawa
- Tomoki Suichi (ORCID: https://orcid.org/0000-0002-9575-9444)
- Marie Morooka
- Moeko Ogushi
- Nagisa Oshima‐Hasegawa
- Yusuke Takeda
Institutions
- Chiba University (JP)
- Chiba University Hospital (JP)
Funders
- Ministry of Health, Labour and Welfare